PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 19, 2025World Journal of Meta-Analysis2 citationsOpen Access

Reevaluating aminosalicylates role in maintaining remission in ulcerative colitis: Systematic review and meta-analysis in the era of biologics

View Full Paper
TMT MudegeJSJonathan Soldera

Key Points

  • To assess the role of aminosalicylates in maintaining remission in ulcerative colitis, particularly in context of newer therapies.
  • Conducted a systematic review and meta-analysis using data from MEDLINE, EMBASE, and Cochrane Library.
  • Included randomized controlled trials from 2003 to 2024 with quiescent ulcerative colitis patients.
  • Analyzed outcomes such as remission maintenance and adverse events using Cochrane methods.
  • 5-ASA was superior to placebo in maintaining remission with a relapse rate of 37% vs 55% for placebo.
  • Serious adverse events were rare and similar between treatment groups.
  • The analysis suggested that 5-ASA remains viable alongside advanced therapies with different safety profiles.

Abstract

BACKGROUND Oral 5-aminosalicylic acid (5-ASA) has been a cornerstone treatment for mild to moderate ulcerative colitis (UC), traditionally used to maintain remission. With the rise of advanced therapies (biologics and small molecules), the role of 5-ASA has come under renewed scrutiny. While earlier systematic reviews affirmed its efficacy compared to placebo, these did not account for the advent of advanced therapies. AIM To assess the efficacy and safety of oral 5-ASA in maintaining remission in quiescent UC, compared to placebo, alternative 5-ASA formulations, and advanced therapies, in the era of biologics and small molecules. METHODS It was systematically searched MEDLINE, EMBASE, and the Cochrane Library, alongside conference proceedings (European Crohn’s and Colitis Organisation, British Society of Gastroenterology), for randomized controlled trials published between 2003 and 2024 in English. Eligible studies involved oral 5-ASA therapies for quiescent UC with a minimum treatment duration of six months. Outcomes included failure to maintain remission, adverse events, and serious adverse events (SAEs). Data were analyzed using Cochrane methods, with GRADE assessing evidence certainty. RESULTS From 44 studies (9967 participants), 5-ASA was superior to placebo in maintaining remission, with 37% of 5-ASA users relapsing at 6-12 months compared to 55% of placebo users risk ratios (RR): 0.68; 95%CI: 0.61-0.76; high-certainty evidence. SAEs were rare and comparable between groups (RR: 0.60; 95%CI: 0.19-1.84; low-certainty evidence). Comparative analyses suggested 5-ASA remains a viable option alongside advanced therapies, with notable differences in cost and safety profiles. CONCLUSION 5-ASA remains effective and safe for maintaining remission in quiescent UC, even in the advanced therapy era. However, tailored approaches are needed to balance efficacy, safety, and cost in clinical practice. This study provides critical insights to guide therapeutic strategies and underscores the enduring relevance of 5-ASA.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mudege et al. (2025) studied this question.

synapsesocial.com/papers/69449a892f0218eca95083eehttps://doi.org/10.13105/wjma.v13.i4.108681
Ask AI
Helpful
Bookmark
Share
View Full Paper